Clinical Trial

RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This research study is studying a combination of targeted therapies as a possible treatment for estrogen-receptor positive (ER+) endometrial cancer. The drugs involved in this study are: * Abemaciclib (also known as Verzenio™) * Letrozole (also known as Femara®) * Metformin (also known as Glucophage®) * Gedatolisib (also known as PF-05212384)
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2018-09-14; most recent amendment 2026-06-18.
Status change: Active, Not Recruiting → Recruiting 2025-06-12
Status change: Recruiting → Active, Not Recruiting 2024-11-05
Status change: Not Yet Recruiting → Recruiting 2019-01-02
Trial Details
NCT Number NCT03675893
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Eli Lilly and Company, Celcuity Inc
Conditions Endometrial Cancer
Enrollment 110 participants
Start Date 2018-12-24
Primary Completion 2028-08-01 (estimated)
Study Completion 2031-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-22